Abstract: A compound that is useful for inhibiting FXIIIa catalysis of fibrin cross-linking, and related pharmaceutical compositions and methods, are disclosed. The compound and compositions may be advantageously used to enhance fibrinolysis and resolution of blood clots.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
January 20, 1998
Assignees:
Zymo Genetics, Inc., Novo Nordisk A/S
Inventors:
Robert R. West, Teresa Martinez, Hank R. Franklin, Paul D. Bishop, Birgitte R.o slashed.mer Rassing
Abstract: The present invention provides a method and apparatus for determining the presence of solid tumor tissue, for identifying and mapping the margins of solid tumors during surgical or diagnostic procedures, and for grading and characterizing tumor tissue by detecting changes in the optical properties of an area of interest suspected to contain tumor tissue.
Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding a novel human amyloid protein precursor homologue and novel Kunitz-type inhibitors. Also provided are DNA constructs comprising a first DNA segment encoding a novel human amyloid protein precursor homologue or a novel Kunitz-type inhibitor wherein said first DNA segment is operably linked to additional DNA segments required for the expression for the first DNA segment, as well as host cells containing such DNA constructs and methods for producing proteins from the host cells.
Type:
Grant
Filed:
April 18, 1995
Date of Patent:
October 14, 1997
Assignee:
Zymogenetics, Inc.
Inventors:
Cindy A. Sprecher, Donald C. Foster, Kjeld E. Norris
Abstract: The present invention comprises homeopathic dilutions of growth factors and methods for their use. Disorders which may be effectively treated with the compositions of the present invention include chronic viral disorders, such as HIV, AIDS, chronic fatigue syndrome and Epstein-Barr viral infections, cancer and diabetes. Homeopathic dilutions of growth factors are preferably administered orally. In an alternative embodiment, patients are treated with radio frequency signals corresponding to homeopathic dilutions of growth factors.
Abstract: The present invention comprises homeopathic dilutions of growth factors and methods for their use. Disorders which may be effectively treated with the compositions of the present invention include chronic viral disorders, such as HIV, AIDS, chronic fatigue syndrome and Epstein-Barr viral infections, cancer and diabetes. Homeopathic dilutions of growth factors are preferably administered orally. In an alternative embodiment, patients are treated with electromagnetic signals, preferably radiofrequency signals, corresponding to homeopathic dilutions of growth factors.
Abstract: Antibodies raised against derivatives of inositol are used to assay for specific isomers of inositol in a sample by first converting any inositol present in the sample to the derivative that was used to raise the antibody and then conducting an immunoassay for the inositol derivative in a conventional manner.
Type:
Grant
Filed:
February 2, 1994
Date of Patent:
June 11, 1996
Assignee:
The University of Virginia Patent Foundation
Inventors:
Joel Linden, Thomas Piccariello, George Vandenhoff
Abstract: An enhanced quantitative assay for chiro-inositol concentration can be used to determine insulin-resistance, or a predisposition to the development of insulin-resistance, in type I and type II diabetics. Spot urine or serum samples reflecting concentrations of chiro-inositol below about 1.0 micrograms/ml in urine or 0.1 micrograms/ml in serum are indicative of a predisposition to the development of insulin-resistance, while concentrations below about 0.3 micrograms/ml or 0.03 micrograms/ml in serum are associated with actual insulin-resistance symptoms. The assay can be employed for patient diagnosis, insulin therapy monitoring, and family screening.
Type:
Grant
Filed:
September 30, 1992
Date of Patent:
June 27, 1995
Assignee:
The University of Virginia Patent Foundation
Abstract: A method of treating a cluster of diseases associated with elevated blood sugar levels comprising the administration of a dietary supplement of chiro-inositol. Chiro-inositol is an essential element for the synthesis of an insulin-directed mediator apparently responsible for the activation of pyruvate dehydrogenase-phosphatase. Disease conditions commonly associated with insulin-resistance, such as hypertension, lactic acidosis, obesity, coronary artery disease, and the like, are treated by administration of sufficient chiro-inositol to meet normal metabolic levels.
Type:
Grant
Filed:
September 12, 1994
Date of Patent:
June 27, 1995
Inventors:
Joseph Larner, Alison Kennington, Laura C. Huang
Abstract: The invention relates to the synthesis of D-chiro-inositol from glucodialdose comprising the steps of condensing glucodialdose by a acylon condensation reaction, protecting the carbon atoms of the 1,2,5 and 6 position, epimerizing the protected carbon atom at position 5, reducing the ketone of the condensed compound and removing the protect groups.
Abstract: The present invention is a foot operated control device that provides variable control by means of a single foot pedal. The foot operated control device can be locked to allow continuous unattended operation. The foot pedal can be flipped into an upper position, for example into a cabinet. In a preferred embodiment of the invention, the foot operated control device comprises a foot operated faucet.